	Type	Hits	Search Text	DBs	Time Stamp	Ref #
1	IS&R	2	(("5595997") or ("4659716")).PN.	USPAT	2005/05/18 13:30	S1
2	BRS	21	anhydrous core	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 16:48	S2
3	BRS	1	non-hygroscopic core	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:45	S3
4	BRS	1172	inert same film-forming same film same coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:45	S4
5	BRS	21	inert film-forming same coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:48	S5
6	BRS	13	inert film-forming same coated	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:49	S6
7	BRS	2487	hydroxypropyl methylcellulose same coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:52	S7
8	IS&R	112726	("514").CLAS.	USPAT	2005/05/18 13:50	S8
9	BRS	675	S7 and S8	USPAT	2005/05/18 13:51	S9
10	BRS	1233	hydroxypropyl methylcellulose near5 (coat or coating or coated)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:58	S13
11	BRS	543	hydroxypropyl methylcellulose near3 (coat or coating or coated)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S14

	Type	Hits	Search Text	DBs	Time Stamp	Ref #
12	BRS	26	S14 same standard	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:55	S15
13	BRS	130	S13 same standard	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:55	S16
14	BRS	0	S13 and antihistimine	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:56	S17
15	BRS	3	S13 and antihistamine.ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:56	S18
16	BRS	1590	methylcellulose near5 (coat or coating or coated)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:59	S19
17	BRS	1643	standard coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S20
18	BRS	46	S20 and S8	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S21
19	BRS	1281	common coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S22
20	BRS	26	S22 and S8	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S23

(FILE 'HOME' ENTERED AT 16:52:36 ON 18 MAY 2005)

FILE 'REGISTRY' ENTERED AT 16:52:42 ON 18 MAY 2005
L1 1 S DESCARBOETHOXYLORATADINE

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, USPATFULL' ENTERED AT 16:53:06 ON 18 MAY 2005
L2 1317 S DESCARBOETHOXYLORATADINE OR L1
L3 453 S L2 AND P/DT
L4 864 S L2 NOT L3
L5 44 S L3 AND PY<1998
L6 272 S L2 AND LACTOSE
L7 270 DUP REM L6 (2 DUPLICATES REMOVED)
L8 5 S L2 AND LACTOSE-FREE
L9 5 DUP REM L8 (0 DUPLICATES REMOVED)
L10 2 S L2 AND (FREE (5W) (LACTOSE OR CARBOHYDRATE))
L11 9 S SECONDARY (P) AMINE (P) INCOMPATIB? (P) (CARBOHYDRATE OR LACT
L12 9 DUP REM L11 (0 DUPLICATES REMOVED)

L9 ANSWER 1 OF 5 USPATFULL on STN
AN 2004:239228 USPATFULL
TI Compositions and methods for treating colic
IN Burrell, David, Wake Forest, NC, UNITED STATES
PI US 2004185032 A1 20040923
AI US 2003-689539 A1 20031021 (10)
PRAI US 2003-455417P 20030318 (60)
DT Utility
FS APPLICATION
LREP MCDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC, 20005-3096
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1382
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for providing relief from pain and/or discomfort associated with gastrointestinal disorders, including, for example, bloating, crying, gas, cramping, regurgitation, diarrhea and gastrointestinal pain, associated with colic comprising, at least one antiflatulent, at least one histamine H.sub.1-receptor antagonist, and optionally, one or more prebiotic and/or one or more probiotic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 5 USPATFULL on STN
AN 2002:323075 USPATFULL
TI Methods for treating vertigo and motion sickness using **descarboethoxyloratadine**
IN McCullough, John R., Worcester, MA, UNITED STATES
PA Sepracor Inc. (U.S. corporation)
PI US 2002183241 A1 20021205
AI US 2002-146415 A1 20020516 (10)
RLI Continuation of Ser. No. US 1999-272391, filed on 19 Mar 1999, ABANDONED
Division of Ser. No. US 1997-808116, filed on 28 Feb 1997, GRANTED, Pat. No. US 5939426
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1156
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating urinary incontinence, vertigo and motion sickness comprising administering a therapeutically effective amount of **descarboethoxyloratadine**, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 5 USPATFULL on STN
AN 2002:228343 USPATFULL
TI **Lactose-free**, non-hygroscopic and anhydrous pharmaceutical compositions of **descarboethoxyloratadine**
IN Redmon, Martin P., Marlborough, MA, UNITED STATES
Butler, Hal T., Marlborough, MA, UNITED STATES
Wald, Stephen A., Sudbury, MA, UNITED STATES
Rubin, Paul D., Sudbury, MA, UNITED STATES
PA SEPRACOR INC., Marlborough, MA, UNITED STATES (U.S. corporation)
PI US 2002123504 A1 20020905
AI US 2002-82685 A1 20020225 (10)
RLI Continuation of Ser. No. US 2000-721088, filed on 22 Nov 2000, ABANDONED
Continuation of Ser. No. US 1998-19955, filed on 6 Feb 1998, ABANDONED
PRAI US 1997-53050P 19970721 (60)
US 1997-45184P 19970430 (60)

US 1997-37325P 19970207 (60)
DT Utility
FS APPLICATION
LREP Candice J. Clement, Heslin Rothenberg Farley & Mesiti P.C., 5 Columbia Circle, Albany, NY, 12203
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 995
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Stable pharmaceutical compositions of **descarboethoxyloratadine** (DCL), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compositions are formulated to avoid the incompatibility between DCL and reactive excipients such as lactose and other mono- and di-saccharides. Disclosed compositions include **lactose-free**, non-hygroscopic and anhydrous stable pharmaceutical compositions of DCL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 5 USPATFULL on STN
AN 1999:96377 USPATFULL
TI Methods for treating urinary incontinence using **descarboethoxyloratadine**
IN McCullough, John R., Worcester, MA, United States
PA Sepracor Inc., Marlborough, MA, United States (U.S. corporation)
PI US 5939426 19990817
AI US 1997-808116 19970228 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Moezie, Minna
LREP Pennie & Edmonds LLP
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1145
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for treating urinary incontinence comprising administering a therapeutically effective amount of **descarboethoxyloratadine**, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:548533 CAPLUS
DN 129:180143
TI **Lactose-free**, non-hygroscopic and anhydrous pharmaceutical compositions of **descarboethoxyloratadine**
IN Redmon, Martin P.; Butler, Hal T.; Wald, Stephen A.; Rubin, Paul D.
PA Sepracor, Inc., USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9834614	A1	19980813	WO 1998-US2328	19980206
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 522014	B	20030301	TW 1998-87101236	19980203

	ZA 9800977	A	19980730	ZA 1998-977	19980206
	AU 9862719	A1	19980826	AU 1998-62719	19980206
	EP 969836	A1	20000112	EP 1998-904980	19980206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	NZ 335041	A	20000929	NZ 1998-335041	19980206
	CA 2267136	C	20001128	CA 1998-2267136	19980206
	BR 9806157	A	20010109	BR 1998-6157	19980206
	JP 2001511184	T2	20010807	JP 1998-534919	19980206
	RU 2209627	C2	20030810	RU 1999-107283	19980206
	CN 1132579	B	20031231	CN 1998-802313	19980206
	NO 9902157	A	19990504	NO 1999-2157	19990504
	US 2002123504	A1	20020905	US 2002-82685	20020225
	AU 776837	B2	20040923	AU 2002-45909	20020611
	AU 2002045909	A5	20030327		
PRAI	US 1997-37325P	P	19970207		
	US 1997-45184P	P	19970430		
	US 1997-53050P	P	19970721		
	AU 1998-62719	A3	19980206		
	US 1998-19955	B1	19980206		
	WO 1998-US2328	W	19980206		
	US 2000-721088	B1	20001122		

GI



I

AB Stable pharmaceutical compns. of **descarboethoxyloratadine** (DCL) (I), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compns. are formulated to avoid the incompatibility between I and reactive excipients such as lactose and other mono- and di-saccharides. Tablets were prepared containing I 10, starch 60, talc 12, acacia 12, and stearic acid 1 mg/tablet.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 1 OF 9 USPATFULL on STN
AN 2003:237907 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003166064 A1 20030904
AI US 2002-99926 A1 20020314 (10)
RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 9 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)
US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 9 USPATFULL on STN
AN 2003:17986 USPATFULL
TI STABLE DOSAGE FORMS OF FLUOXETINE AND ITS ENANTIOMERS
IN REDMON, MARTIN P., MARLBOROUGH, MA, UNITED STATES
BUTLER, HAL T., MARLBOROUGH, MA, UNITED STATES
WALD, STEPHEN A., MARLBOROUGH, MA, UNITED STATES
PI US 2003013740 A1 20030116
AI US 1998-49227 A1 19980327 (9)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1306
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chemically and physically stable pharmaceutical formulations, of the potent antidepressant, fluoxetine, its enantiomers and salts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 9 USPATFULL on STN
AN 2002:308396 USPATFULL
TI Pharmaceutical compositions comprising norastemizole
IN Redmon, Martin P., Oxford, MA, UNITED STATES
Butler, Hal T., Marlborough, MA, UNITED STATES
Wald, Stephen A., Sudbury, MA, UNITED STATES
PI US 2002173522 A1 20021121
AI US 2002-75616 A1 20020215 (10)
RLI Continuation-in-part of Ser. No. US 2000-719843, filed on 21 Nov 2000, ABANDONED A 371 of International Ser. No. WO 1998-US5701, filed on 25 Mar 1998, UNKNOWN Continuation-in-part of Ser. No. US 1997-851786, filed on 6 May 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-824477, filed on 26 Mar 1997, ABANDONED Continuation-in-part of Ser. No. US 2000-721711, filed on 27 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 1997-851786, filed on 6 May 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-824477, filed on 26 Mar 1997, ABANDONED
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to chemically stable pharmaceutical formulations of the potent antihistamine, norastemizole. The compositions can include norastemizole, or a pharmaceutically acceptable salt thereof; a diluent; a binder; a disintegrant; and a lubricant or the compositions can include particles of norastemizole, or a pharmaceutically acceptable salt thereof, coated with an inert coating and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating allergic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 9 USPATFULL on STN
AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002150922 A1 20021017
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 9 USPATFULL on STN
AN 2002:243051 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2002132237 A1 20020919
AI US 2001-867701 A1 20010529 (9)
PRAI US 2000-207484P 20000526 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 25718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 9 USPATFULL on STN
AN 2002:242791 USPATFULL

TI . Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2002131971 A1 20020919
AI US 2001-33528 A1 20011226 (10)
RLI Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8083
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 9 USPATFULL on STN
AN 2001:25463 USPATFULL
TI Stabilized thyroxine medications
IN Groenewoud, Pieter J., 4 Westover Ct., Yardley, PA, United States 19067
PI US 6190696 B1 20010220
AI US 1999-327256 19990607 (9)
RLI Continuation-in-part of Ser. No. US 1998-92819, filed on 8 Jun 1998, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Channavajjala, Lakshmi
LREP Wobensmith, III, Zachary T.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Thyroxine medications which include combinations of levothyroxine, and/or liothronine, or dextrothyroxine, or thyroid, and one or more iodine salts, or iodine donor compounds are described, which produce a stable thyroxine medication, with a long shelf life. A method for manufacturing the medications is also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1970:136347 CAPLUS
DN 72:136347
TI Incompatibility of lactoses and amines
AU Ritschel, W. A.; Ritschel-Beurlin, Gerda
CS Coll. of Pharm., Univ. of Cincinnati, Cincinnati, OH, USA
SO Praeparative Pharmazie (1970), 6(2), 21-8
CODEN: PPKKBD; ISSN: 0370-1220
DT Journal

LA German

AB Thirty-two different amines were investigated for their **incompatibility** with **lactose** alone and with **lactose** with Mg stearate or stearic acid. All the amines gave a discoloration at least in one of the prepns. after 8-weeks storage in a hygrostat at 95% relative humidity and 40°. The discolorations occurred earlier and to a greater extent in tablets (pressed mixts.) than in powders. A dependence of the discoloration on the kind of **amine** (primary, **secondary**, tertiary, quaternary) and on the change of pH could not be found.